TABLE 3

Insulin signaling protein expression before and after treatment with troglitazone or placebo

Troglitazone group
Placebo group
BeforeAfterBeforeAfter
IBC (fmol/mg)
 Basal22.0 ± 2.624.6 ± 3.523.1 ± 3.121.2 ± 3.5
 Clamp23.2 ± 3.225.6 ± 3.925.7 ± 3.922.8 ± 3.0
IRS-1 (% of standard)
 Basal138 ± 3393 ± 1180 ± 2188 ± 17
 Clamp97 ± 1696 ± 20104 ± 23104 ± 25
PKB (% of standard)
 Basal143 ± 28183 ± 51122 ± 23122 ± 25
 Clamp120 ± 18188 ± 57119 ± 2499 ± 23
IRS-2 (AU)
 Basal1.26 ± 0.311.20 ± 0.250.93 ± 0.430.73 ± 0.24
 Clamp1.22 ± 0.280.90 ± 0.220.76 ± 0.230.99 ± 0.28
PDK-1 (AU)
 Basal0.88 ± 0.111.08 ± 0.150.83 ± 0.120.90 ± 0.10
 Clamp1.04 ± 0.181.20 ± 0.141.03 ± 0.121.04 ± 0.21
GLUT-4 (AU)
 Basal0.81 ± 0.081.01 ± 0.200.84 ± 0.210.95 ± 0.13
 Clamp1.14 ± 0.180.98 ± 0.151.24 ± 0.261.08 ± 0.12
  • Data are means ± SE; n = 8–10. Insulin binding capacity (IBC) in the skeletal muscle lysates was determined as described in research design and methods and expressed per milligram solubilized muscle protein. The amounts of the other proteins were determined by the separation of muscle lysates with similar protein concentration by SDS-PAGE and subsequent immunoblots with the respective antibodies. AU, arbitrary units.